Evidence supporting the use of: Curcumin
For the health condition: Fibromyalgia Syndrome

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the primary active compound in turmeric, has been investigated for its potential benefits in managing Fibromyalgia Syndrome (FMS), though evidence is still emerging and somewhat limited. The rationale for its use is primarily based on curcumin’s well-documented anti-inflammatory, antioxidant, and neuroprotective properties. FMS is characterized by chronic widespread pain, fatigue, and cognitive disturbances, with underlying mechanisms believed to involve neuroinflammation, oxidative stress, and dysregulation of pain signaling pathways. Several preclinical studies have suggested curcumin may attenuate neuropathic pain, reduce pro-inflammatory cytokines, and modulate oxidative stress, all of which are relevant to FMS pathophysiology.

Clinical evidence, however, is sparse. A handful of small pilot studies and case reports have investigated curcumin supplementation in patients with FMS or similar chronic pain disorders, reporting modest improvements in pain, fatigue, and quality of life. For example, a 2021 randomized controlled trial found that a curcumin-piperine combination reduced pain scores in FMS patients over 8 weeks compared to placebo, though the sample size was small and the study duration short. Most clinical data come from related conditions such as arthritis or neuropathic pain, with extrapolation to FMS. Thus, while there is scientific rationale and some preliminary support, robust, large-scale clinical trials are lacking.

In summary, curcumin’s use in FMS is justified by preclinical and limited clinical evidence, but it is not yet considered a standard or well-validated treatment. More research is needed to substantiate its efficacy and safety for this indication.

More about curcumin
More about Fibromyalgia Syndrome